Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America
Human papillomavirus
Genotype Distribution
Genotype
Epidemiology
Science
Human Papillomavirus and Cervical Cancer Epidemiology
Uterine Cervical Neoplasms
Microbiology
Gene
03 medical and health sciences
Vaginal Microbiome and Sexually Transmitted Infections
0302 clinical medicine
Health Sciences
Genetics
Humans
Papillomaviridae
Internal medicine
Biology
Cancer
Immunology and Microbiology
Human papillomavirus 16
Cervical intraepithelial neoplasia
Hepatitis B Infection and Treatment
Q
Papillomavirus Infections
R
Cohort
Gastroenterology
Life Sciences
Uterine Cervical Dysplasia
Latin America
Oncology
Gynecology
FOS: Biological sciences
Cervical cancer
Medicine
Female
HPV Vaccination
Research Article
DOI:
10.1371/journal.pone.0272205
Publication Date:
2022-07-29T17:35:32Z
AUTHORS (26)
ABSTRACT
The proportion of HPV16 and 18-associated cervical cancer (CC) appears rather constant worldwide (≥70%), but the relative importance other HR-HPV differs slightly by geographical region. Here, we studied HPV genotype distribution positive Latin American (LA) women histological grade, in a sub-cohort from ESTAMPA study; also explored association age-specific genotypes severe lesions. Cervical samples 1,252 participants (854 ≤CIN1, 121 CIN2, 194 CIN3 83 CC) were genotyped two PCRs-Reverse Blotting Hybridization strategies: i) Broad-Spectrum General Primers 5+/6+ ii) PGMY9/11 PCRs. was most frequently found all grades, increased with severity lesions 14.5% ≤ CIN1, 19.8% 51.5% to 65.1% CC (p < 0.001). For remaining HR-HPVs their frequency did not increase when compared less categories. nonavalent vaccine HR-types ranked at top CC, dominant ones being HPV45. single infection occurs, respectively, 57.1% 57.0% ≤CIN1 increasing 72.2% 91.6% (p<0.001). No between age type observed although risk cases age. Results confirm relevance whole clinical spectrum, strong rise its cancer. This information will be relevant evaluating impact vaccination, as baseline against which compare changes type-specific vaccinated participate screening LA Likewise, these data may help select best testing system for HPV-based efficient, affordable, sustainable programmes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (64)
CITATIONS (30)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....